A Study of SGN-PDL1V in Advanced Solid Tumors
Status: RECRUITING
Study type: INTERVENTIONAL
Conditions: Carcinoma, Non-Small-Cell Lung|Squamous Cell Carcinoma of the Head and Neck|Esophageal Squamous Cell Carcinoma|Ovarian Neoplasms|Melanoma|Triple Negative Breast Neoplasms|Gastric Cancer
Interventions: DRUG: SGN-PDL1V|DRUG: pembrolizumab
Sponsor: Seagen Inc.